Blog Posts
Q3 2026 Highlights – Partnership for the U.S. Life Science Ecosystem (PULSE)
PULSE continues to spotlight the unique and fundamental role of mergers and acquisitions (M&A) and other collaborations in supporting America’s innovative life sciences ecosystem.
A Predictable M&A Environment Supports the Early-Stage Risk-Taking Behind New Medicines
A recent Financial Times article highlights a rising challenge for America’s life sciences ecosystem: as biotechnology fundraising has declined, venture capital (VC) investors are increasingly prioritizing later-stage drug candidates that offer the prospect of faster returns.
Innovations Advanced by M&A: A First-in-Class Treatment for Pulmonary Arterial Hypertension
Merck’s 2021 acquisition of Acceleron Pharma is one example of how M&A can help bring new treatments to market and support continued innovation.
Why M&A Is a Driver of Rare Disease Innovation
A new BioSpace article highlights an urgent challenge: maintaining America’s leadership in developing rare disease treatments amid increasing global competition. Meeting that challenge will require policies that support the full life sciences innovation ecosystem – including pro-competitive M&A, which help connect rare disease innovation to the resources and capabilities needed to reach patients.
Innovations Advanced by M&A: A New Therapy to Slow Geographic Atrophy Progression
Astellas’ 2023 acquisition of Iveric Bio is one of many examples demonstrating how M&A can help support the transition from initial development to commercialization and continued innovation.
Q2 2026 Highlights – Partnership for the U.S. Life Science Ecosystem (PULSE)
PULSE continues to build awareness of the unique and fundamental role of life sciences mergers and acquisitions (M&A) and other pro-competitive partnerships. Read below for a round-up of recent PULSE updates and commentaries. Advocating for Balanced Competition...
States Must Preserve Balanced Approach to Life Sciences Antitrust Enforcement
Policymakers in California, New York and across the country are considering state-level antitrust proposals that could chill innovation, competition and growth in key industries, including life sciences.
PULSE Urges FTC, DOJ to Support Pro-Competitive Life Sciences Collaborations and M&A
In recent comments to the Department of Justice (DOJ) and Federal Trade Commission (FTC), PULSE highlighted critical reforms to ensure that U.S. competition policies support – and do not impede – the pro-competitive mergers and acquisitions (M&A) and other collaborations that drive American life sciences innovation.
Q&A with PULSE Partner BioNJ on the Local Impact of Life Sciences M&A
PULSE recently sat down for a conversation on life sciences M&A with Debbie Hart, President and CEO at BioNJ, the life sciences trade association for New Jersey.
By the Numbers: Citeline’s R&D Annual Review Underscores Importance of Life Sciences M&A
Findings from Citeline’s latest report, Pharma R&D Annual Review 2026, highlight the continued U.S. leadership in the life sciences ecosystem.